Evidence map›Paper›PMID 26252270›Full record

SynthesisMedicine2015

Genetic Association Between NFKBIA -881A>G Polymorphism and Cancer Susceptibility.

Peiliang Geng, Juanjuan Ou, Jianjun Li, Yunmei Liao, Ning Wang, Rina Sa, Lisha Xiang, Houjie Liang

Abstract readMeta-AnalysisReview
In one paragraph

Synthesis in Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peiliang GengFrom the Department of Oncology and Southwest Cancer Center, Southwest Hospital Third Military Medical University, Chongqing, China.
Juanjuan Ou
Jianjun Li
Yunmei Liao
Ning Wang
Rina Sa
Lisha Xiang
Houjie Liang

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several epidemiological studies have focused on the role of nuclear factor-kappa-B inhibitor-alpha (NFKBIA) -881 A>G polymorphism in cancer susceptibility. However, the published data have led to contentious results. This study was designed to examine the association between -881 A>G polymorphism and cancer risk.Comprehensive search of PubMed, Web of science and Embase, identified a total of 5 case-control studies. To assess the association, comparison among all subjects plus subgroup analysis by ethnicity was performed and odds ratio (OR) along with 95% confidence interval (CI) was calculated with the fixed-effect model or the random-effects model dependent on the heterogeneity.The pooling data consisting of 1965 cancer cases and 2717 cancer-free controls demonstrated no significant association with overall cancer risk. However, the subgroup of Asian populations showed statistical evidence for an increase in risk of cancer (GG vs. AA, OR, 2.14; 95% CI, 1.03-4.46; GG + GA vs. AA, OR, 1.22; 95% CI, 1.01-1.47; GG vs. GA + AA, OR, 2.09; 95% CI, 1.01-4.34).This investigation on the association of -881 A>G polymorphism and cancer susceptibility reveals that -881 A>G polymorphism may act as a candidate for cancer development in Asian populations.

Indexed as

Genetic Predisposition to DiseasePolymorphism, Single NucleotideAsian PeopleBiomarkers, TumorGenetic Association StudiesGenetic MarkersHumansI-kappa B ProteinsModels, StatisticalNeoplasmsNF-KappaB Inhibitor alphaBiomarkers, TumorGenetic MarkersI-kappa B ProteinsNF-KappaB Inhibitor alphaNFKBIA protein, human

Identifiers

PMID26252270
PMCPMC4616602

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.